GenNext Portfolio
The GenNext portfolio by Progressive Investment, LLC aims to invest in global equities of companies driving the genomic revolution. These companies are actively engaged in or benefit from improving human and other life forms by leveraging advancements in genomics, incorporating technological and scientific innovations. They offer products or services that utilize genomic sequencing, analysis, synthesis, or specialized instruments. This portfolio includes companies across diverse sectors—healthcare, information technology, materials, energy, and consumer discretionary. It may also invest in companies that develop, manufacture, or heavily rely on bionic devices, bio-inspired computing, bioinformatics, molecular medicine, and agricultural biotechnology.
Our Services
1
Potential for Growth
Seeks to achieve long-term growth with minimal correlation to traditional growth strategies and an inverse correlation to value strategies.
2
Innovation Exposure
Seeks thematic multi exposure to innovative areas such as gene therapy, bioinformatics, bio-inspired computing, molecular medicine, and advancements in pharmaceuticals.
3
Based on Research
Integrates both top-down and bottom-up research in portfolio management to discover innovative companies and market convergence.
GenNext Portfolio: Innovation and Disruption in Biotechnology and Advanced Therapies
The GenNext portfolio by Progressive Investment, LLC consists of a selection of innovative companies in the fields of biotechnology and health technology. These companies are at the forefront of medical technology, developing disruptive solutions that are transforming healthcare and human well-being. Below are the highlights that make this portfolio a high-potential investment:
Growth Potential
The companies in this portfolio operate in sectors experiencing rapid growth. Factors such as an aging population, the demand for personalized treatments, and ongoing advancements in advanced therapies are driving innovation in these areas. Technologies like genetic editing, precision medicine, and artificial intelligence applied to biomedicine are revolutionizing the industry, offering new growth opportunities for these companies.
​
Innovation and Disruption
The GenNext portfolio is both innovative and disruptive, encompassing companies that apply emerging technologies in their businesses, such as:
-
Genetic Editing: Companies like CRISPR Therapeutics and Beam Therapeutics are leading in genetic editing technology, offering solutions with the potential to cure hereditary diseases.
-
Artificial Intelligence and Bioinformatics: Companies like Tempus AI and Schrodinger are applying artificial intelligence and data analysis to enhance diagnostic accuracy and optimize drug discovery.
-
Next-Generation Biotechnology: Companies like 10X Genomics and Adaptive Biotechnologies are transforming genetic analysis and immunotherapy, developing products that significantly improve the treatment of various diseases.
-
Advanced Biomedical Devices: Companies such as Butterfly Network and 908 Devices innovate in diagnostic tools and portable medical devices, facilitating access to high-precision technology.
Sector Classification
This portfolio covers several key sectors within modern biotechnology and health:
-
Genomics and Gene Therapy: Includes leading companies in genetic editing and genomic analysis, such as CRISPR Therapeutics and Illumina.
-
Precision Medicine: Companies developing personalized treatments based on genetic profiles, like Natera and Guardant Health.
-
Diagnostics and Bioinformatics: Companies focused on advanced diagnostics and medical data analysis, like Exact Sciences and Tempus AI.
-
Advanced Pharmaceutical Therapies: Companies innovating in biological therapies and targeted treatments, like Vertex Pharmaceuticals and Moderna.
-
Next-Generation Medical Devices: Companies producing high-tech medical devices, such as Butterfly Network and 908 Devices.
A Portfolio for the Future of Health
The GenNext portfolio by Progressive Investment, LLC represents a commitment to technologies revolutionizing the health and biotechnology industries. By investing in genomics, advanced therapies, precision diagnostics, and medical devices, investors gain exposure to rapidly expanding sectors with exponential growth potential.
This portfolio not only reflects current progress in biotechnology but also positions investors in areas that will define the future of modern medicine.